^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TNFRSF17 (TNF Receptor Superfamily Member 17)

    i
    Other names: TNFRSF17, TNF Receptor Superfamily Member 17, Tumor Necrosis Factor Receptor Superfamily Member 17, B-Cell Maturation Protein, BCMA, Tumor Necrosis Factor Receptor Superfamily, Member 17, B Cell Maturation Antigen, B-Cell Maturation Factor, CD269 Antigen, TNFRSF13A, CD269
    6d
    The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D. (PubMed, Leukemia)
    Importantly, BCMA status predicted benefit from BCMA re-treatment. Hepta-refractory MM is marked by profound genomic complexity, antigen loss, and poor outcomes, highlighting the need for novel therapies and broader diagnostics such as integrated genomic and IHC testing for this ultra-refractory population.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • TNFRSF17 (TNF Receptor Superfamily Member 17)
    12d
    A Case of Primary IgG-κ with κ Free Light Chain Plasma Cell Leukemia with Literature Review. (PubMed, Clin Lab)
    For primary plasma cell leukemia, we should pay attention to the changes in the abnormal morphology and number of plasma cells. With the help of bone marrow smear, flow cytometry and other tests, we can make a clear diagnosis as early as possible and actively carry out treatment at an early stage.
    Retrospective data • Review • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • B2M (Beta-2-microglobulin) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule)
    1m
    BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape. (PubMed, Semin Hematol)
    We then summarize the clinical development and distinguishing features of currently approved BCMA-targeted modalities-CAR T-cell therapies (ide-cel, cilta-cel), bispecific T-cell engagers (teclistamab, elranatamab, linvoseltamab), and the antibody-drug conjugate (belantamab mafodotin)-highlighting their efficacy, toxicity profiles, and practical positioning in relapsed/refractory MM. Finally, we review emerging resistance mechanisms, including γ-secretase-driven sBCMA elevation, ligand-rich APRIL/BAFF niches, and therapy-induced TNFRSF17 lesions, ranging from biallelic deletions to epitope-altering missense mutations and in-frame deletions within the BCMA extracellular domain. These insights inform rational strategies such as γ-secretase inhibition, dual-target CAR T-cells and bispecific T-cell engagers.
    Journal • IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    Elrexfio (elranatamab-bcmm) • Blenrep (belantamab mafodotin-blmf) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel) • Tecvayli (teclistamab-cqyv) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma. (PubMed, bioRxiv)
    This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    TNFRSF17 expression
    2ms
    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)
    Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    lenalidomide • bortezomib • cyclophosphamide
    2ms
    Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells. (PubMed, Biochem Pharmacol)
    In xenograft models, CAR-T cells significantly prolonged median survival. Thus, UCB-derived anti-MSLN CAR-Ts showed reduced exhaustion, increased memory T cell proportions, and enhanced anti-tumor efficacy in vitro and in vivo.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF17 (TNF Receptor Superfamily Member 17) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    3ms
    Integrating machine learning and experimental validation identifies a post-translational modification gene signature for prognosis and treatment response in breast cancer. (PubMed, Sci Rep)
    SLC27A2 mRNA expression was elevated in tumor tissues relative to adjacent noncancerous tissues, whereas the mRNA expression levels of the other four genes were decreased. This study reveals the important role of PTMs in BC prognosis and provides new perspectives for the prognostic assessment of BC patients as well as personalized treatment.
    Journal • Gene Signature • IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17) • FUT3 (Fucosyltransferase 3) • COL17A1 (Collagen Type XVII Alpha 1 Chain)
    4ms
    Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis. (PubMed, Int Immunopharmacol)
    These findings were further corroborated by our single-cell RNA data and multiplex immunohistochemistry results, which provided additional substantiation for the observed interactions. These observations regarding the interaction between the tumor microenvironment and nasopharyngeal carcinoma have significant clinical implications for the future treatment of NPC.
    Journal
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand) • TNFRSF4 (TNF Receptor Superfamily Member 4) • CD48 (CD48 Molecule) • OASL (2'-5'-Oligoadenylate Synthetase Like) • CD80 (CD80 Molecule)
    4ms
    Mechanistic study of ANXA3-mediated endoplasmic reticulum stress promoting M1 macrophage polarization in pulmonary arterial hypertension based on bioinformatics and nine machine learning algorithms. (PubMed, Comput Biol Med)
    This study demonstrates that ANXA3 regulates ERS to drive M1 macrophage polarization and inflammation, which subsequently promotes PASMC function and promotes PAH progression. ANXA3 may serve as a novel immunoinflammatory target and potential therapeutic candidate.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CD68 (CD68 Molecule) • IL18 (Interleukin 18) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF4 (Activating Transcription Factor 4) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • IL1B (Interleukin 1, beta) • ANXA3 (Annexin A3) • TCF4 (Transcription Factor 4)
    |
    semaxanib (SU5416)
    4ms
    Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection. (PubMed, Blood Adv)
    Deletions and mutations were detected in TNFRSF17 encoding BCMA in patients treated with anti-BCMA regimens, and the information was used to change the treatment of the patients. Targeted sequencing of multiple myeloma patient diagnostic samples can be used for risk stratification and also to monitor and adjust treatments as resistance mechanisms evolve.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CRBN (Cereblon) • TNFRSF17 (TNF Receptor Superfamily Member 17) • SDC1 (Syndecan 1) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
    |
    TP53 mutation
    5ms
    Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis. (PubMed, J Med Biochem)
    Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients. CD184 and CD269 may serve as valuable prognostic markers in MM patients.
    Retrospective data • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    TNFRSF17 expression
    5ms
    Tumor-educated platelet RNA as a diagnostic biomarker for ground-glass opacity-related lung adenocarcinoma. (PubMed, Transl Lung Cancer Res)
    We further discovered that AHNAK had a low expression in the tissues and TEPs of patients with LUAD presenting as GGOs, and we further validated its diagnostic efficacy and in vitro tumor-suppressive effects. The downregulation in AHNAK may be associated with changes in the ribosomal pathway, affecting the malignancy of tumors.
    Journal • IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)